INTRODUCTION: Assessing the impact of migraine preventive treatments on acute medication consumption is important in clinical evaluation. The number of acute medication intakes per each monthly migraine day (MMD) could provide insights on migraine burden and represent a new proxy of treatment effectiveness in clinical trials and real-life studies. We evaluated the effect of monoclonal antibodies acting on calcitonin gene-related peptide (CGRP) pathway on the consumption of migraine acute medication in real-life. METHODS: In two headache centers in Prague (CZ), we included and followed up to 6 months consecutive patients treated with MoAbs acting on CGRP (erenumab or fremanezumab). For each month of treatment, we reported monthly drug intake (MDI) in doses of any medication, migraine-specific (MS), and non-migraine-specific (non-MS) medications, and computed a ratio between MMDs and MDI, i.e., Migraine Medication Index (MMI) for MS and non-MS medications. RESULTS: We included 90 patients (91.1% women) with a median age of 47 [interquartile range (IQR) 42-51] years; 81 (90.0%) treated with erenumab and 9 (10.0%) with fremanezumab. Median MMDs decreased from 11 (IQR 8-14) at baseline to 4 (IQR 2-5) at Month 3 (p < 0.001 vs. baseline) and 3 (IQR 2-6) at Month 6 (p < 0.001 vs. baseline). Median MDI decreased from 15 drug intakes (IQR 11-20) at baseline to four drug intakes (IQR 2-7) at Month 3 (p < 0.001) and four drug intakes (IQR 2-7) at Month 6 (p < 0.001).The corresponding MDIs for MS medications were 10 (IQR 6-14) at baseline, 3 (IQR 1-5, p < 0.001) at Month 3, and 2 (IQR 0-4, p < 0.001) at Month 6. Monthly drug intakes for non-MS medications were 4 (IQR 0-9) at baseline, 1 (IQR 0-3, p < 0.001) at Month 3 and at Month 6.Median MMI decreased from 1.32 (IQR 1.11-1.68) at baseline to 1.00 (IQR 1.00-1.50, p < 0.001) at Month 3 and 1.00 (IQR 1.00-1.34, p < 0.001) at Month 6. CONCLUSIONS: We confirmed that MoAbs acting on CGRP pathway decrease acute migraine medication consumption. We proposed a new index that can be easily applied in clinical practice to quantify migraine burden and its response to acute medication. Our index could help optimizing migraine acute treatment in clinical practice.

Department of Neurology 1st Faculty of Medicine Military University Hospital Prague Charles University Prague Czechia

Department of Neurology 2nd Faculty of Medicine Motol University Hospital Prague Charles University Prague Czechia

Neuroscience Section Department of Applied Clinical Sciences and Biotechnology University of L'Aquila L'Aquila Italy

Zobrazit více v PubMed

Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z L L, on behalf of Lifting The Burden: the Global Campaign against Headache . Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. J Headache Pain. (2020) 21:137. 10.1186/s10194-020-01208-0 PubMed DOI PMC

Cooper W, Doty EG, Hochstetler H, Hake A, Martin V. The current state of acute treatment for migraine in adults in the United States. Postgrad Med. (2020) 132:581–9. 10.1080/00325481.2020.1767402 PubMed DOI

Thorlund K, Toor K, Wu P, Chan K, Druyts E, Ramos E, et al. . Comparative tolerability of treatments for acute migraine: a network meta-analysis. Cephalalgia. (2017) 37:965–78. 10.1177/0333102416660552 PubMed DOI

Leroux E, Buchanan A, Lombard L, Loo LS, Bridge D, Rousseau B, et al. . Evaluation of patients with insufficient efficacy and/or tolerability to triptans for the acute treatment of migraine: a systematic literature review. Adv Ther. (2020) 37:4765–96. 10.1007/s12325-020-01494-9 PubMed DOI PMC

Wakerley BR. Medication-overuse headache. Pract Neurol. (2019) 19:399–403. 10.1136/practneurol-2018-002048 PubMed DOI

Burch R. Preventive migraine treatment. Continuum (Minneap Minn). (2021) 27:613–32. 10.1212/CON.0000000000000957 PubMed DOI

Edvinsson L. CGRP antibodies as prophylaxis in migraine. Cell. (2018) 175:1719. 10.1016/j.cell.2018.11.049 PubMed DOI

De Matteis E, Guglielmetti M, Ornello R, Spuntarelli V, Martelletti P, Sacco S. Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives. Expert Rev Neurother. (2020) 20:627–41. 10.1080/14737175.2020.1772758 PubMed DOI

Tepper SJ, Ashina M, Reuter U, Hallstrom Y, Broessner G, Bonner JH, et al. . Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials. J Headache Pain. (2021) 22:81. 10.1186/s10194-021-01292-w PubMed DOI PMC

Silvestro M, Orologio I, Bonavita S, Scotto di Clemente F, Fasano C, Tessitore A, et al. . Effectiveness and safety of CGRP-mAbs in menstrual-related migraine: a real-world experience. Pain Ther. (2021) 10:1203–14. 10.1007/s40122-021-00273-w PubMed DOI PMC

Headache Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders , 3rd edition. Cephalalgia. (2018) 38:1–211. 10.1177/0333102417738202 PubMed DOI

Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, et al. . European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. (2019) 20:6. 10.1186/s10194-018-0955-y PubMed DOI PMC

American Headache S . The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. (2019) 59:1–18. 10.1111/head.13496 PubMed DOI

Yang M, Rendas-Baum R, Varon SF, Kosinski M. Validation of the headache impact test (HIT-6) across episodic and chronic migraine. Cephalalgia. (2011) 31:357–67. 10.1177/0333102410379890 PubMed DOI PMC

Lambru G, Hill B, Murphy M, Tylova I, Andreou AP. A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain. (2020) 21:61. 10.1186/s10194-020-01127-0 PubMed DOI PMC

Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA, et al. . Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain. (2020) 21:32. 10.1186/s10194-020-01102-9 PubMed DOI PMC

Russo A, Silvestro M, Scotto di Clemente F, Trojsi F, Bisecco A, Bonavita S, et al. . Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience. J Headache Pain. (2020) 21:69. 10.1186/s10194-020-01143-0 PubMed DOI PMC

Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, et al. . Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. (2018) 392:2280–7. 10.1016/S0140-6736(18)32534-0 PubMed DOI

Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R, et al. . Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. (2019) 394:1030–40. 10.1016/S0140-6736(19)31946-4 PubMed DOI

Mulleners WM, Kim BK, Lainez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S, et al. . Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. (2020) 19:814–25. 10.1016/S1474-4422(20)30279-9 PubMed DOI

Ailani J, Andrews JS, Rettiganti M, Nicholson RA. Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials). J Headache Pain. (2020) 21:123. 10.1186/s10194-020-01190-7 PubMed DOI PMC

Cheng S, Jenkins B, Limberg N, Hutton E. Erenumab in chronic migraine: an australian experience. Headache. (2020) 60:2555–62. 10.1111/head.13968 PubMed DOI

Raffaelli B, Kalantzis R, Mecklenburg J, Overeem LH, Neeb L, Gendolla A, et al. . Erenumab in chronic migraine patients who previously failed five first-line oral prophylactics and onabotulinumtoxin A: a dual-center retrospective observational study. Front Neurol. (2020) 11:417. 10.3389/fneur.2020.00417 PubMed DOI PMC